InnoCare’s Mesutoclax obtains breakthrough therapy designation in China
This designation is intended for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). Mesutoclax becomes the inaugural BCL2 inhibitor to receive BTD recognition in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.